EUVIMEDEUVIMED entdecken
Open Access

A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma

Zesheng An, Michelle A Hsu iD, Joanina K Gicobi iD, Tianxiao Xu, Susan M Harrington, Henan Zhang, Kevin D Pavelko iD, Jacob B Hirdler, Christine M Lohse, Reza Nabavizadeh, Rodrigo R Pessoa, Vidit Sharma und 4 weitere

The Journal of Immunology · 2023

DOI: 10.4049/jimmunol.2200933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Zesheng An und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Antineoplastic Agents, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, HHS | NIH | National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The intrinsic and acquired resistance to PD-1/PD-L1 immune checkpoint blockade is an important challenge for patients and clinicians because no reliable tool has been developed to predict individualized response to immunotherapy. In this study, we demonstrate the translational relevance of an ex vivo functional assay that measures the tumor cell killing ability of patient-derived CD8 T and NK cells (referred to as “cytotoxic lymphocytes,” or CLs) isolated from the peripheral blood of patients with renal cell carcinoma. Patient-derived PBMCs were isolated before and after nephrectomy from patients with renal cell carcinoma. We compared the efficacy of U.S. Food and Drug Administration (FDA)-approved PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, atezolizumab) and a newly developed PD-L1 inhibitor (H1A Ab) in eliciting cytotoxic function. CL activity was improved at 3 mo after radical nephrectomy compared with baseline, and it was associated with higher circulating levels of tumor-reactive effector CD8 T cells (CD11ahighCX3CR1+GZMB+). Treatment of PBMCs with FDA-approved PD-1/PD-L1 inhibitors enhanced tumor cell killing activity of CLs, but a differential response was observed at the individual-patient level. H1A demonstrated superior efficacy in promoting CL activity compared with FDA-approved PD-1/PD-L1 inhibitors. PBMC immunophenotyping by mass cytometry revealed enrichment of effector CD8 T and NK cells in H1A-treated PBMCs and immunosuppressive regulatory T cells in atezolizumab-treated samples. Our study lays the ground for future investigation of the therapeutic value of H1A as a next-generation immune checkpoint inhibitor and the potential of measuring CTL activity in PBMCs as a tool to predict individual response to immune checkpoint inhibitors in patients with advanced renal cell carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellAntineoplastic AgentsKidney NeoplasmsHumansImmune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorLeukocytes, MononuclearT-Lymphocytes, RegulatoryNephrectomyCD8-Positive T-Lymphocytes

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Immunology, Mayo Clinic, Rochester, MN.
  • Department of Urology, Mayo Clinic, Rochester, MN.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
  • Immune Monitoring Core, Mayo Clinic, Rochester, MN.
  • Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.

ORCID-Profile: Michelle A Hsu, Joanina K Gicobi, Kevin D Pavelko, Bradley C Leibovich, Haidong Dong, Fabrice Lucien

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • HHS | NIH | National Cancer Institute
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

An, Z., Hsu, M. A., Gicobi, J. K., Xu, T., Harrington, S. M., Zhang, H., Pavelko, K. D., Hirdler, J. B., Lohse, C. M., Nabavizadeh, R., Pessoa, R. R., Sharma, V., Thompson, R. H., Leibovich, B. C., Dong, H., & Lucien, F. (2023). A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2200933

Vancouver

An Z, Hsu MA, Gicobi JK, Xu T, Harrington SM, Zhang H, et al. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2200933

BibTeX
@article{An2023,
  author = {An, Zesheng and Hsu, Michelle A and Gicobi, Joanina K and Xu, Tianxiao and Harrington, Susan M and Zhang, Henan and Pavelko, Kevin D and Hirdler, Jacob B and Lohse, Christine M and Nabavizadeh, Reza and Pessoa, Rodrigo R and Sharma, Vidit and Thompson, R Houston and Leibovich, Bradley C and Dong, Haidong and Lucien, Fabrice},
  title = {A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma},
  journal = {The Journal of Immunology},
  year = {2023},
  doi = {10.4049/jimmunol.2200933}
}
Kostenlos starten →